Physician profile
Stanley S Wang
NPI 1962592071
$1,627.02
in general payments reported to CMS, 2019-2025
27 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.23 · 2020: $202 · 2021: $61.73 · 2022: $23.96 · 2023: $462 · 2024: $370 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $227.31 | 2023-2025 | Camzyos, Eliquis |
| Medicure Pharma INC. | $199.64 | 2020-2023 | Zypitamag |
| Pfizer INC. | $140.62 | 2019-2024 | |
| Inspire Medical Systems, INC. | $122.21 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $119.37 | 2019-2025 | |
| Amgen INC. | $92.56 | 2024-2025 | Repatha |
| Lexicon Pharmaceuticals, INC. | $80.73 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $75.50 | 2025 | Evkeeza, Praluent |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.63 | 2023 | Lifevest |
| Heartflow, INC. | $55.25 | 2025 | |
| 3b Medical, INC. | $53.53 | 2024-2025 | Luna |
| Abiomed | $42.78 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.61 | 2025 | Jardiance |
| Itamar Medical INC | $36.80 | 2021-2023 | Watchpatone |
| Avadel Cns Pharmaceuticals, LLC | $36.55 | 2023-2024 | Lumryz |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $26.85 | 2024 | Remede System |
| Esperion Therapeutics, INC. | $24.60 | 2023 | Nexletol |
| Baxter Healthcare | $24.12 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Boston Scientific Corporation | $22.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.76 | 2023 | Xarelto |
| Azurity Pharmaceuticals, INC. | $21.44 | 2023 | Edarbi |
| Novartis Pharmaceuticals Corporation | $20.67 | 2024 | |
| Cleerly, INC. | $16.81 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Strongbridge US INC. | $16.30 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.02 | 2024 | Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $14.12 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.